TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›IVVD›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Invivyd, Inc. (IVVD) financials

Income statement

Invivyd, Inc. (IVVD) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Revenue———$0.00$25.4M$53.4M
Revenue growth—————110.5%
Operating income—-$227M-$248M-$213M-$177M-$55.6M
Operating margin————-696.8%-104.0%
Net income—-$227M-$241M-$199M-$170M-$52.5M
Net margin————-669.4%-98.2%
EPS (diluted)—-$5.32-$2.23-$1.81-$1.43-$0.30

Cash flow

Invivyd, Inc. (IVVD) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow—-$185M-$220M-$173M-$170M-$58.1M
Capital expenditures—$84.0K$1.71M$615K$140K$155K
Free cash flow—-$185M-$222M-$174M-$171M-$58.3M
Share buybacks—$0.00$4.00K$1.00K$0.00—

Balance sheet

Invivyd, Inc. (IVVD) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$115M$542M$92.1M$201M$69.3M$227M
Total assets$117M$620M$383M$229M$130M$277M
Total liabilities$13.1M$62.1M$27.2M$51.7M$62.0M$35.3M
Shareholders' equity-$65.2M$558M$356M$177M$67.5M$242M
Retained earnings-$65.3M-$292M-$533M-$732M-$902M-$954M
Shares (wtd avg diluted)5.59M42.6M108M110M119M172M

Every figure is extracted from Invivyd, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Invivyd, Inc.'s annual revenue?
Invivyd, Inc. (IVVD) reported $53.4M of revenue for fiscal year 2025 — up 110.5% from $25.4M in FY2024, per its annual report filed with the SEC.
Is Invivyd, Inc. profitable?
Not in FY2025 — IVVD reported a net loss of $52.5M, per SEC filings.
What is Invivyd, Inc.'s free cash flow?
-$58.3M in FY2025 (operating cash flow -$58.1M minus $155K of capital expenditures), from the SEC cash-flow statement.
Does IVVD pay a dividend?
Invivyd, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full IVVD analysis — verdict, score & filings →Is IVVD a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.